Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

NCT05410821 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Refractory Thyroid Gland Carcinoma
Refractory Thyroid Gland Papillary Carcinoma
Refractory Thyroid Gland Follicular Carcinoma
Refractory Thyroid Gland Hurthle Cell Carcinoma

Interventions

DRUG: 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
DRUG: 177Lu-DOTA-EB-FAPI 2 radionuclide therapy
DRUG: 177Lu-DOTA-EB-FAPI 3 radionuclide therapy

Sponsor

The First Affiliated Hospital of Xiamen University